v3.25.1
Statement of profit or loss and other comprehensive income - AUD ($)
 6 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Profit or loss [abstract]    
Other income $ 22,290 $ 5
Finance Income 28,667 6,453
Expenses    
Research and development expense (4,282,101) (4,327,717)
General and administrative expense (5,108,573) (4,555,691)
Fair value (loss)/gain on financial liabilities (1,999,648) 84,587
Gain/(loss) on revaluation of contingent consideration 750,008 (166,696)
Loss before income tax benefit (10,589,357) (8,959,059)
Income tax benefit 135,546 135,546
Loss after income tax benefit for the half-year attributable to the owners of Kazia Therapeutics Limited (10,453,811) (8,823,513)
Items that may be reclassified subsequently to profit or loss    
Net exchange difference on translation of financial statements of foreign controlled entities, net of tax 174,335 (103,687)
Other comprehensive income for the half-year, net of tax 174,335 (103,687)
Total comprehensive income for the half-year attributable to the owners of Kazia Therapeutics Limited $ (10,279,476) $ (8,927,200)
Earnings per share for loss from continuing operations attributable to the owners of Kazia Therapeutics Limited    
Basic earnings per share $ (2.459) $ (3.68)
Diluted earnings per share $ (2.459) $ (3.68)